04 June 2015
: Case report
A Patient with Urinary Tract Tuberculosis During Treatment with Etanercept
Unusual clinical course, Mistake in diagnosis, Diagnostic / therapeutic accidents, Unexpected drug reaction , Educational Purpose (only if useful for a systematic review or synthesis)
Shiho ShibataABCDEF, Eisuke ShonoBD, Emi NishimagiE, Ken YamauraEDOI: 10.12659/AJCR.893416
Am J Case Rep 2015; 16:341-346
Abstract
BACKGROUND: Tumor necrosis factor (TNF)-α inhibitors are widely used for rheumatoid arthritis (RA). However, there are several risks to use TNFα inhibitors. Given the properties of TNF-α inhibitors, prevention and early detection of tuberculosis (TB) are especially important. Even among TNF-α inhibitors, the risk of TB infection differs according to each drug. The incidence of TB is lowest with etanercept (ETN). We present a case of urinary tract TB during treatment with ETN.
CASE REPORT: A 58-year-old woman was receiving ETN for RA. Before starting ETN, isoniazid (INH) prophylaxis was started. RA was well controlled by ETN. However, 32 months after starting ETN, she noticed urinary frequency and a sensation of residual urine. The diagnosis was elusive, and it took 3 months until urinary tract TB was finally diagnosed. The TB resolved with antituberculosis medication, but RA disease activity flared up after ETN was discontinued. ETN was resumed with careful monitoring for TB recurrence. After resuming ETN, the RA was again well controlled, with no recurrence of TB.
CONCLUSIONS: Patients should be monitored for development of TB during ETN treatment, but ETN can be used safely with careful management.
Keywords: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use, Antitubercular Agents - therapeutic use, Arthritis, Rheumatoid - drug therapy, Etanercept - therapeutic use, Follow-Up Studies, Tomography, X-Ray Computed, Tuberculosis, Urogenital - drug therapy
924 3
In Press
25 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939239
24 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939520
24 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939697
23 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939642
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347